EPA-540/1-86-010
                         I wi iinci uol
                      Agency
Office of Emergency and
Remedial Response
Washington DC 20460
                      Superfund
&EPA
Off'ce of Research and Development
Office of Health and Environmental
Assessment
Environmental Criteria and
Assessment Office
Cincinnati OH 45268
                       HEALTH  EFFECTS ASSESSMENT
                       FOR  CHLOROFORM

-------
                                           EPA/540/1-86-010
                                           September  1984
       HEALTH EFFECTS  ASSESSMENT
              FOR CHLOROFORM
    U.S. Environmental  Protection  Agency
     Office of Research and  Development
Office of Health  and  Environmental Assessment
Environmental Criteria  and Assessment Office
            Cincinnati,  OH  45268
    U.S. Environmental Protection  Agency
  Office of  Emergency  and Remedial Response
Office of Solid Waste and  Emergency  Response
            Washington, DC  20460

-------
                                  DISCLAIMER

    This  report  has  been  funded  wholly  or  1n  part  by  the  United States
Environmental  Protection  Agency under  Contract  No.  68-03-3112  to  Syracuse
Research Corporation.  It has  been  subject to the Agency's peer and  adminis-
trative review, and  It has  been  approved  for  publication as an EPA document.
Mention of  trade  names or  commercial  products  does  not  constlti/te  endorse-
ment or recommendation for use.
                                      11

-------
                                    PREFACE
    This report  summarizes  and evaluates Information relevant  to  a prelimi-
nary  Interim  assessment  of  adverse health  effects  associated with  chloro-
form.  All estimates of  acceptable  Intakes  and  carcinogenic potency present-
ed 1n  this  document  should  be considered as  preliminary  and reflect  limited
resources  allocated  to  this  project.   Pertinent  toxlcologlc  and  environ-
mental data were located  through  on-Hne  literature  searches of the Chemical
Abstracts,  TOXLINE,  CANCERLINE  and  the  CHEMFATE/DATALOG  data bases.   The
basic  literature  searched   supporting   this   document   1s  current   up  to
September,  1984.   Secondary  sources  of  Information have  also been  relied
upon  in  the  preparation of  this  report  and  represent  large-scale  health
assessment  efforts  that entail  extensive   peer  and  Agency  review.   The
following Office of  Health  and Environmental Assessment  (OHEA)  sources  have
been extensively utilized:

    U.S. EPA.   1980b.   Ambient Water  Quality  Criteria  for Chloroform.
    Environmental  Criteria  and Assessment Office, Cincinnati,  OH.  EPA
    440/5-80-033.  NTIS PB 81-117442.   (Cited 1n U.S. EPA, 1982}

    U.S. EPA.   1982.   Hazard  Profile  for Chloroform.  Prepared by the
    Environmental  Criteria  and Assessment Office, Cincinnati,  OH, OHEA
    for  the  Office of  Solid  Waste  and Emergency  Response, Washington,
    DC.

    U.S.  EPA.    1983b.    Review  of  Toxlcological  Data   1n Support  of
    Evaluation  for Carcinogenic  Potential  of Chloroform.   Prepared  by
    the  Carcinogen  Assessment Group,   OHEA,   Washington,   DC  for  the
    Office of Solid Waste and Emergency Response, Washington, DC.

    U.S.  EPA.   1984.    Health   Assessment   Document  for   Chloroform.
    Environmental  Criteria   and  Assessment   Office,  Research  Triangle
    Park, NC.   EPA 600/8-84-004A.   NTIS PB 84-195163.

    The Intent in  these assessments 1s  to  suggest  acceptable exposure levels
whenever sufficient data  were available.   Values were not  derived or  larger
uncertainty factors  were employed  when  the  variable data were  limited  in
scope  tending to generate conservative  (I.e.,  protective) estimates.   Never-
theless, the Interim values  presented  reflect the relative  degree of  hazard
associated with exposure or  risk to  the chemical(s) addressed.

    Whenever possible,  two categories of  values  have been estimated for  sys-
temic  toxicants (toxicants for which cancer  1s  not the  endpolnt of concern).
The  first,  the AIS  or  acceptable  Intake  subchronic, 1s  an estimate of  an
exposure  level  that would  not  be  expected  to cause  adverse effects  when
exposure occurs  during  a limited time  Interval (I.e.,  for  an  Interval  that
does  not  constitute  a  significant  portion of  the Hfespan).   This  type  of
exposure estimate  has  not  been  extensively  used  or rigorously defined,  as
previous  risk  assessment  efforts   have  been  primarily  directed  towards
exposures from toxicants  1n  ambient air or water  where  lifetime exposure  1s
assumed.  Animal   data  used  for  AIS  estimates  generally  Include exposures
with  durations  of  30-90 days.  Subchronic  human data are  rarely  available.
Reported exposures are  usually  from chronic  occupational  exposure  situations
or from reports  of  acute accidental  exposure.
                                      111

-------
    The  AIC,  acceptable  Intake  chronic,  Is  similar 1n  concept  to  the  ADI
(acceptable  dally  Intake).   It  Is  an  estimate  of an  exposure  level  that
would not  be expected  to cause  adverse effects  when  exposure occurs  for  a
significant portion  of  the lifespan  [see  U.S.  EPA  (1980a) for a  discussion
of  this   concept].   The  AIC  Is  route specific  and  estimates   acceptable
exposure  for  a given  route with  the  Implicit  assumption  that exposure  by
other routes 1s Insignificant.

    Composite  scores  (CSs)  for  noncarclnogens  have  also  been  calculated
where data  permitted.   These  values  are used for  ranking  reportable  quanti-
ties; the methodology for their development Is explained  1n U.S.  EPA (1983a).

    For compounds for which there  Is  sufficient  evidence  of  cardnogenldty,
AIS  and  AIC values  are not derived.   For a  discussion  of risk  assessment
methodology for  carcinogens  refer to  U.S. EPA  (1980a).   Since cancer  1s  a
process  that 1s  not  characterized by  a threshold, any exposure  contributes
an Increment of risk.   Consequently,  derivation of AIS and AIC values  would
be Inappropriate.  For  carcinogens,   q-|*s  have been computed  based  on  oral
and Inhalation  data If  available.
                                      1v

-------
                                   ABSTRACT
    In order to  place  the risk assessment evaluation  1n  proper  context,  the
reader Is  referred to  the  preface of  this  document.  The  preface  outlines
limitations applicable to all  documents of this  series  as well  as the appro-
priate Interpretation and use of the quantitative estimates.

    Chloroform  has  been  shown  to  be  carcinogenic  by  the oral  route  in
rodents 1n  several  independent investigations.   Human data  are  limited,  but
suggestive.  The  Carcinogen  Assessment  Group (U.S.  EPA,  1984)  has  used  the
following  data:   liver  tumors  in  female  mice  (NCI,  1976);  liver tumors  1n
male  mice  (NCI,  1976);  kidney tumors  in male  rats  (NCI, 1976);  and kidney
tumors in  male  mice (Roe et  al.,  1979).   There was no compelling reason  to
select any  one of  these data  sets over the  others;  therefore,  the geometric
mean of the slope (q-j*), 7xlO~2 (mg/kg/day)"1,  was used.

    Data  are not  available  which would allow  an assessment of  the  carcino-
genic potential  of chloroform following  inhalation exposure.

-------
                               ACKNOWLEDGEMENTS
    The  Initial  draft  of  this  report  was  prepared  by  Syracuse  Research
Corporation under  Contract No.  68-03-3112  for EPA's  Environmental  Criteria
and  Assessment  Office,  Cincinnati,  OH.   Dr.  Christopher  DeRosa and  Karen
Blackburn were the Technical Project Monitors  and  Helen Ball  was^the Project
Officer.  The final documents  In  this  series  were  prepared for the Office of
Emergency and Remedial Response, Washington. DC.

    Scientists from  the  following U.S. EPA offices  provided  review  comments
for this document series:

         Environmental Criteria and Assessment Office, Cincinnati, OH
         Carcinogen Assessment Group
         Office of Air Quality Planning and Standards
         Office of Solid Waste
         Office of Toxic Substances
         Office of Drinking Water

Editorial review for the document series was provided by:

    Judith Olsen and Erma Durden
    Environmental Criteria and Assessment Office
    Cincinnati, OH

Technical support services for the document series  was provided by:

    Bette Zwayer, Pat Daunt, Karen Mann and Jacky Bohanon
    Environmental Criteria and Assessment Office
    Cincinnati, OH
                                      v1

-------
                              TABLE  OF  CONTENTS

1.
2.


3.








4.








5.
6.





7.

ENVIRONMENTAL CHEMISTRY AND FATE 	
ABSORPTION FACTORS IN HUMANS AND EXPERIMENTAL ANIMALS . . .
2.1. ORAL 	
2.2. INHALATION 	 '. .
TOXICITY IN HUMANS AND EXPERIMENTAL ANIMALS 	
3.1. SUBCHRONIC 	
3.1.1. Oral 	
3.1.2. Inhalation 	
3.2. CHRONIC 	
3.2.1. Oral 	
3.2.2. Inhalation 	
3.3. TERATOGENICITY AND OTHER REPRODUCTIVE EFFECTS. . . .
3.4. TOXICANT INTERACTIONS 	
CARCINOGENICLTY 	
4.1. HUMAN DATA 	
4.1.1. Oral 	
4.1.2. Inhalation 	
4.2. BIOASSAYS 	
4.2.1. Oral 	
4.2.2. Inhalation 	
4.3. OTHER RELEVANT DATA 	
4.4. WEIGHT OF EVIDENCE 	
REGULATORY STANDARDS AND CRITERIA 	
RISK ASSESSMENT 	
6.1. ACCEPTABLE INTAKE SUBCHRONIC (AIS) 	
6.2. ACCEPTABLE INTAKE CHRONIC (AIC) 	
6.3. CARCINOGENIC POTENCY (q-j*) 	
6.3.1. Oral 	
6.3.2. Inhalation 	
REFERENCES 	
Page
1
. . . 2
. . . 2
2
3
3
. . . 3
. . . 3
5
. . . 5
, , 5
. . . 6
, , 6
7
7
. . . 7
7
7
. . . 7
10
. . . 10
11
. . . 12
13
. . . 13
. . . 13
13
. . . 13
. . . 13
. . . 14
APPENDIX: Summary Table for Chloroform 	   23

-------
                             LIST  OF  ABBREVIATIONS





ADI                     Acceptable daily Intake



AIC                     Acceptable Intake chronic



AIS                     Acceptable intake subchronic



bw                      Body weight



CAS                     Chemical abstract service



CS                      Composite score



LOAEL              .     Lowest-observed-adverse-effect level



ppm                     Parts per million



STEL                    Short-term exposure limit



TLV                     Threshold limit value



TWA                     Time-weighted average
                                     viil

-------
                     1.   ENVIRONMENTAL CHEMISTRY  AND  FATE

    The relevant physical  and  chemical  properties and environmental fate  of
chloroform (CAS No.  67-66-3)  are as  follows:
Chemical class:

Molecular weight:
Vapor pressure:

Water solubility:
                                       halogenated   aliphatic    hydrocarbon
                                       (purgeable halocarbon)
                                       119.38 (Callahan et a!.,  1979)
                                       150.5 mm Hg at 20°C (Callahan et al.,
                                       1979)
                                       8200 mg/8,  at 20°C  (Callahan et al.,
                                       1979)
Octanol/water partition
coefficient:
Soil mobility:
(predicted as retardation factor
 for a soil depth of 140 cm and
 organic carbon content of 0.087%)
B1oconcentrat1on factor:
(1n bluegUl, Lepomis macrochlrus)
Half-life 1n air:
Half-life in water:
                                       93 (Callahan et al.,  1979)
                                       1.2 (Wilson et al.,  1981)


                                       6 (Barrows  et al.,  1978)

                                       80 days (U.S. EPA,  1982)
                                       0.3-3  days  In  rivers   (Zoeteman  et
                                       al.,  1980)
                                       3-30  days  in lakes  (Zoeteman et  al.,
                                       1980)

    The half-life of  chloroform  1n  soil could not  be  located  in  the  litera-
ture searched.  However,  evaporation  is expected  to be the  predominant  loss
mechanism from the  soil  surface.   The half-life for  soil evaporation  should
be  longer  than  its evaporation  half-life  from water.   In  subsurface  soil,
blodegradatlon of chloroform  Is  likely  to  be a weak, very  slow  process  (no
degradation  in  27  weeks)  (Wilson  et  al.,  1983).   Therefore,  1n  subsurface
soil, chloroform Is expected  to remain  stable enough to leach Into  ground-
water.
                                     -1-

-------
           2.  ABSORPTION  FACTORS IN HUMANS AND EXPERIMENTAL ANIMALS
2.1.   ORAL
    Evidence from  human  assays (Fry  et  al., 1972),  as  well  as  from  animal
experiments (Brown et  al.,  1974;  Taylor  et al., 1974),  indicates  that -100%
of Ingested chloroform is  absorbed  from the gastrointestinal  tract.
2.2.   INHALATION
    From 49-77% of the chloroform present  1n  the inspired  air  1s  absorbed  by
the lungs (U.S.  EPA,  1980b).
                                     -2-

-------
               3.  TOXICITY  IN HUMANS AND EXPERIMENTAL ANIMALS
3.1.   SUBCHRONIC
    Table 3-1  presents a  summary of  the  effects  of subchronlc  chloroform
exposure.
3.1.1.    Oral.    DeSalva  et  al.   (1975)  reported  that  chloroform  at  dose
levels  of 1.0  and 2.5 mg/kg/day  for  a  1-year period produced no  effects  on
the functioning of the human liver and kidney.
    No  effects 1n  rats were reported at dose levels of 15 and  30 mg/kg/day
(Palmer  et   al.,  1979).   However,  dose  levels  of  150 and  410  mg/kg/day
produced severe toxic effects, such as necrosis  of  the  liver  and dysfunction
of the  gonads (Palmer et al., 1979).
3.1.2.    Inhalation.   Torkelson et al.  (1976) exposed rats, guinea  pigs  and
rabbits  to  25,  50 and 80  ppm (122,  244 and  415 mg/m3, respectively)  for  7
hours/day, 4 days/week for 6 months  (Table 3-1).   Exposure  to  25 ppm chloro-
form produced  hlstopathologlcal  changes 1n  the Hvers  and kidneys  of male
but  not  female  rats.   At higher  doses,  lobular  granular  degeneration  and
focal  necrosis were  Increased 1n  the  liver,  and cloudy swelling  of epithe-
lial cells  was  Increased  In  the  kidney.   These changes were reported  to  be
reversible after  6 weeks.   Hematologlcal,  clinical  chemistry and  urinalysls
values  were  "within   normal  limits."  The results  obtained from  chloroform
exposure  In guinea  pigs   and  rabbits  are  difficult to   Interpret  because
adverse  effects  are  seen  at  the  low  dose  (25  ppm)  and high dose  (85 ppm)
levels, but  no effects are reported at the  Intermediate  dose level  (50 ppm).
    Ep1dem1olog1cal  studies of humans exposed  to chloroform 1n  the workplace
at  levels ranging from 22-237  ppm have Indicated  that depression,  gastro-
intestinal  disturbances  (e.g.,  flatulence,   nausea),  headache  and  frequent
and  scalding urination  are  the   primary  symptoms  (Challen  et  al.,  1958;
                                      -3-

-------
                                                                          TABLE  3-1
                                                              Subchronlc Toxtclty of Chloroform
Route Dose or Exposure
Inhalation 0 ppm
25 ppm (122 mg/m»)
50 ppm (244 mg/m»)
85 ppm (415 mg/m»)
25 ppm (122 mg/m')


Inhalation 0 ppra
25 ppm (122 mg/n»)
50 ppm (244 mg/m*)
85 ppm (415 mg/m")
i Inhalation 0 ppm
•f 25 ppm (122 mg/m»)
50 ppm (244 mg/m»)
85 ppm (415 mg/m»)


Oral 0
1.0 mg/kg/day
2.5 rag/kg/day

Oral 0
15 mg/kg/day
30 mg/kg/day
150 mg/kg/day
410 mg/kg/day
Duration of
Treatment
7 hours/day,
5 days/week
for 6 months

4 hours/day.
5 days/week

7 hours/day,
5 days/week
up to 203 days

7 hours /day.
5 days/week
up to 203 days



1 year



13 weeks




Species/Strain Sex
rats/NR N/f
H/F
H/F
H/F
H/F


guinea plgs/NR H/F
H/F
H/F
H/F
rabblts/NR H/F
H/F
H/F
H/F


human NR



rats/ H/F
Sprague-Dawley



Number
Treated
10-12
10-12
10-12
10-12
10


16-24
16-24
16-24
16-24
4-6
4-6
4-6
4-6


NR



20
20
20
20
20
Effect
Exposure to chloroform at 25 ppm for 4
hours/day had no effect on male mice; at 25
ppm for 7 hours/day, hlstopathologlc changes
In the liver were present In males but not
females; at higher doses. Increasingly pro-
nounced changes were present In the liver and
kidneys of both sexes.-
Pneumonltls was seen In females exposed to
85 ppm, and hlstopathologtcal changes were
observed In the livers and kidneys of both
sexes exposed to 25 ppm but not 50 ppm.
Hepatic and renal pathology was seen In fe-
males exposed to 85 ppm, and pneumonltls and
hepatic necrosis In males exposed to 85 ppm.
Hlstopathologlcal changes were observed In
the livers and kidneys of both sexes exposed
to 25 ppm but not 50 ppm.
Liver and kidney function tests Indicated
that there were no statistically significant
differences between chloroform-treated Indi-
viduals and controls.
Increased liver weight with fatty necrosis,
gonadal atrophy and cellular proliferation
In the bone marrow occurred at 410 and 150
mg/kg/day. No effects were reported for
dose levels of 30 and 15 mg/kg/day.
Reference
Torkelson
et al., 1976





Torkelson
et al., 1976


Torkelson
et al., 1976




DeSalva
et al., 1975


Palmer
et al., 1979



NR = Not reported

-------
Bomskl  et  al.  1967).   Regarding long-term  effects,  Challen  et  al.  (1958)
reported  that  there  was no  evidence of  any  organic  lesion attributable  to
chloroform, based on physical exams and liver function  tests.   Bomskl  et  al.
(1967)  reported  that  chloroform exposure  may result  1n  an Increased  Inci-
dence of viral hepatitis, splenomegaly and hepatomegaly,  although  no statis-
tical analysis  was presented.
3.2.   CHRONIC
3.2.1.    Oral.    Several  chronic oral  studies  (NCI,   1976;  Palmer  et al.,
1979; Roe  et al., 1979) were  designed  to  test the cardnogenlclty  of chloro-
form (see  Chapter 4).   However, depression  of  body  weight  was observed  at
chloroform doses  >60 mg/kg/day  1n  rats (NCI, 1976; Palmer  et  al.,  1979)  and
mice (Roe  et al., 1979).   Decreased relative liver weight  and serum cholin-
esterase  levels   were  reported  In   female  mice  treated  with 60  mg/kg/day
chloroform  (Palmer  et  al.,  1979.)   Higher  chloroform  doses (90  and  180
mg/kg/day)  resulted  1n an  Increased  Incidence  of noncancerous  respiratory
diseases  1n rats (NCI,  1976), and  a  dose of  477  mg/kg/day resulted  In
decreased  female survival  time In  mice  (NCI,  1976).  A  dose level  of  165
mg/kg/day  caused  liver  necrosis and gonadal  atrophy  In rats  (Palmer et al.,
1979).   No effects  were reported to occur 1n rats  at  a dose  of 15 mg/kg/day
(Palmer et al., 1979).
    Chronic  exposure  of humans  to  chloroform appears  to result  in adverse
effects on the central nervous  system (NIOSH,  1974), although there  are no
data on  the dose relation  of the  effects.   In addition,  chloroform affects
the  liver, kidneys and heart  in  humans  (NIOSH,  1974).   The  potential  for
chronic human  oral exposure  to  chloroform has increased because of the wide-
spread practice of chlorinating drinking water (U.S. EPA,  1980b).
3.2.2.    Inhalation.    Pertinent   data  regarding  the   carcinogenicity   of
chloroform Inhalation in humans were not located in the available literature.

                                      -5-

-------
3.3.    TERATOGENICITY AND OTHER REPRODUCTIVE  EFFECTS
    Teratogenlc  effects   (acaudla,   Imperforate  anus,  decreased  crown-rump
length,  missing  ribs  and  delayed  skeletal   ossification)   were  seen   in
Sprague-Dawley  rats  {Schwetz  et  a!.,  1974)  that   inhaled  chloroform for  7
hours/day on  days  6-15 of gestation at  dose levels  of  30,  100 and  300  ppm
(147,  489  and  1466  mg/m3,  respectively).   When CF/1 mice  (Murray  et  a!.,
1979)  were  exposed to  100 ppm chloroform  for  7 hours/day  on days  6-15  of
gestation,  there  was  a  significantly  increased  incidence  of  cleft  palate.
When pregnant  mice and rats were  exposed to 100 ppm  chloroform,  their  food
consumption  and  body weight  decreased,  but  their   relative  liver  weight
Increased (U.S. EPA,  1982).  Ingestion of chloroform  caused  fetotoxldty  but
not  teratogenicity,  and only  at  levels   that  also  produced  severe  maternal
toxicity (Thompson et al., 1974).
3.4.   TOXICANT INTERACTIONS
    The  substances  that   potentiate  the  toxic  effects of  chloroform,  are
methyl  n-butyl ketone (Branchflower  and  Pohl,  1981),  alcohol   (Kutob  and
Plaa,  1961),  carbon  tetrachloride  (Harris et al.,  1982), chlordecone (Iljima
et al.,  1983),  DOT and phenobarbital (McLean,  1970).  Methyl  n-butyl ketone
Increases the toxlcity of chloroform by lowering  glutathione  levels  and  by
Increasing  the  levels  of  hepatic  cytochrome  P-450,  which, in turn, Increases
the  metabolism of chloroform to  phosgene  (Branchflower  and  Pohl,  1981).
Harris  et  al.  (1982)  reported  that  carbon  tetrachloride  potentiated  the
toxic  effects  of  chloroform, because of  Increased  phosgene  formation and the
initiation  of  lipid  peroxldation.   The mechanism of interaction for alcohol,
chlordecone,  DDT  and phenobarbital was  not  discussed,   von  Oettlngen (1964)
reported  that  high-fat/low-protein  diets potentiated  the hepatotoxic effects
of chloroform  in animals.
                                      -6-

-------
                             4.  CARCINOGENICITY
4.1.   HUMAN DATA
4.1.1.   Oral.   Although  chloroform  has  not  unequivocally  been  shown  to
cause human  cancer,  ecological and  case control  studies  (Alavanja et  a!.,
1978; Cantor  et  a!.,  1978;  Brennlman  et  a!.,   1978;  Hogan  et al.,  1979;
Struba,  1979;  Gottlieb  et al., 1981;  Young et al.,  1981)  have  consistently
supported  the association of  Increased risk  of  bladder,  colon and  rectal
cancer with  exposure  to  chloroform,  which  1s  the  predominant  trlhalomethane
contaminating chlorinated drinking water (U.S.  EPA, 1983b).
4.1.2.   Inhalation.   Although exposure  to  airborne chloroform  1n  the  work-
place may  have caused  toxic  effects  (Challen et  al.,  1958; Bomski et  al.,
1967),  and  although  Inhalation  of  chloroform  was  teratogenlc  In  rats
(Schwetz  et  al.,  1974),  pertinent  data   regarding  an association  between
chloroform  Inhalation and  an  Increased Incidence  or  risk of  cancer were not
located In the available literature.
4.2.   8IOASSAYS
4.2.1.   Oral.  Table 4-1  summarizes the available data  from  oral  bloassays
of  chloroform cardnogenlcity.  Eschenbrenner  and Miller  (1945)  emphasized
that  a dose  level  of  chloroform  that caused hepatic necrosis when given once
would cause  hepatic carcinoma  when given repeatedly.   The NCI  (1976) found a
dose-related  Increase In  hepatomas  in  both sexes  when  mice received chloro-
form  in  corn oil  by  gavage,  and an increase  in  renal epithelial  tumors  1n
males when  rats  received  chloroform in  corn oil  by gavage  (Table 4-1).  The
Increased  incidence  of  hepatic  and  renal   tumors  was  statistically signifi-
cant  (p<0.05).   Palmer  et al.  (1979)  criticized  the NCI" study  because rats
being treated with other  volatile  carcinogenic  substances  were housed  1n the
same  room as  the chloroform-treated rats.
                                      -7-

-------
                  TABLE  4-1



Oral Bloassays of Chloroform Carclnogenlclty
Vehicle Dose
NR 150 mg/kg bw
200 mg/kg bw
600 mg/kg bw
1200 mg/kg bw
2400 mg/kg bw





Corn oil 0 mg/kg/day
138 mg/kg/day
277 mg/kg/day
238 mg/kg/day
477 mg/kg/day
0 mg/kg/day
00
i
Corn oil 0 mg/kg/day
90 mg/kg/day
180 mg/kg/day
100 mg/kg/daya
200 mg/kg day a
0 mg/kg day




Toothpaste0 0 mg/kg/day
IS mg/kg day
75 mg/kg/day
165 mg/kg day


Toothpaste*1 0 mg/kg/day
15 mg/kg day
75 mg/kg day
165 mg/kg day
Duration of Duration Species/Strain
Treatment of Study
once every 4 NR mice/
days for a (strain A)
total of 30
doses





S days/week 92-93 weeks m1ce/B6C3Fl
for 78 weeks





5 days/week 111 weeks rats/
for 78 weeks Osborne-Hendel







6 days/week 52 weeks rats/
for 52 weeks Sprague-Dawley




6 days/week 52 weeks rats/
for 52 weeks Sprague-Dawley


Sex
NR






N
N
N
F
F
F


M
N
N
F
F
F




H
N
N
H


F
F
F
F
Number Target
Treated Organ
NR liver






18 liver
50
45
45
41
20


19 kidney
50
50
49
48
20




75 none
25
25
25


75 none
25
25
25
Effects
Doses of 150 and 300 mg/kg bw
produced neither necrosis nor
carcinoma In the liver. Doses
of 600-2400 mg/kg bw produced
necrosis when given once, and
hepatomas when given repeatedly.
All females at the highest dose
and all males at the three
highest doses died early In the
experiment.
Hepatocellular carcinomas were
found In 1/18 (6X) control
males. 18/50 (36X) low-dose
males and 44/45 (98X) high-dose
males; In 0/20 control females,
36/45 (BOX) low-dose females and
39/41 (95X) high-dose females.

Renal carcinomas and adenomas
were found In 0/19 control
males, 4/50 (6X) low-dose males
and 12/50 (24X) high-dose males;
0/20 control females, 0/49 low-
dose females and 2/48 (4X) high-
dose females. Thyroid tumors
were found In 1/20 control
females, 8/49 low-dose females
and 10/48 high-dose females.
No treatment-related neoplastlc
effects were seen In comparison
with controls; however, all
groups had a high Incidence
of pulmonary and renal hlsto-
pathology.
Same as above



Reference
Eschenbrenner
and Miller.
1945






NCI, 1976





NCI. 1976








Palmer
et al.. 1979




Palmer
et al.. 1979



-------
                                                                      TABLE 4-1  (cont.)
Vehicle
Toothpaste0







Toothpaste0






Dose
0 mg/kg/day
60 mg/kg day
0 mg/kg/day
60 mg/kg day




0 mg/kg day
17 mg/kg day
60 mg/kg day

0 mg/kg day
17 mg/kg day
60 mg/kg day
Duration of Duration
Treatment of Study
6 days/week 95 weeks
for 80 weeks






6 days/week 96 weeks
for 96 weeks





Species/Strain Sex
rats/ N
Sprague-Dawleyc N
F
F




rats/NR M
N
N

F
F
F
Number
Treated
50
50
50
50




104
52
52

104
52
52
Target
Organ
none

mammary
gland




kidney



none


Effects
No treatment-related neoplastlc
effects.
Mammary tumors were present In
16/20 control females and 21/50
treated mice; however, there were
significantly more malignant
tumors In the chloroform-exposed
mice (p=0.056)d
Several mice had lymphomas. but
the Incidence was not related
to chloroform exposure. Renal
tumors appeared In the high-dose
males, but In no other group.


Reference
Palmer
et al.. 1979






Roe et al.,
1979





aTMA dose  reflecting Initial dose  levels  of 250  and  125 mg/kg/day  that  were lowered  to 180 and  90  mg/kg/day after 22  weeks  In the high- and  low-dose
 female groups, respectively.
"Toothpaste formulation Included peppermint  oil and eucalyptol (essential oils) as flavor components
cCaesar1an-de!1vered, specific-pathogen-free rats
dS1gn1Mcance of Fischer exact test  as  reported by U.S. EPA (1982)

-------
    Presumably  because  chloroform  has  been  a  contaminant  1n  toothpaste,
British  scientists  treated rats  (Palmer et  al.,  1979),  mice  (Roe et  al.,
1979) and  dogs  (Heywood et  al,  1979) with  chloroform In a  toothpaste  base
Including  essential  oils  as  flavor  components.   Range-finding studies  were
performed  1n  all  experiments.  No effects at  dose  levels of 15, 17 and 165
mg/kg/day for 52 weeks were reported  1n  rats.  When  female rats were treated
with 60  mg/kg/day  for 96  weeks,  however, there was  an Increase (p=0.056)  In
malignant mammary gland tumors 1n the chloroform-treated  group, although the
untreated  group  developed benign  mammary  tumors   (Palmer   et al.,  1979).
There  was  an  Increased Incidence  of kidney  tumors  1n   the  high   dose  (60
mg/kg/day)  level   1n  male  mice   (Roe et  al., 1979).   The  females had  no
Increased  Incidence  of  cancer,  but  there  appeared  to  be  some  confounding
Influence  because of   the vehicle.   The  authors   addressed,  but  did  not
resolve,  the  problem of  the  effect  produced  by  different  vehicles  (Roe  et
al., 1979).
4.2.2.   Inhalation.     Pertinent  data  regarding   the   cardnogenldty   of
Inhaled chloroform were  not located  In the available literature.
4.3.   OTHER RELEVANT DATA
    Chloroform  was not  mutagenlc In  Escher1ch1a  coll strains  K12,  WP2p and
WP2uvrA~p  or  1n Salmonella  typhlmurlum  strains  TA98, TA100,  TA1535,  TA1537
and  TA1538 (Klrkland et  al., 1981),  with  and without metabolic  activation
(S-9).   Chloroform was  not mutagenlc  In  cultured  Ch'lnese  hamster  lung flbro-
blasts  at  the  8-azaguan1ne  locus   (Sturrock,  1977),   nor  did  chloroform
Increase  sister  chromatld  exchanges  1n  cultured Chinese  hamster  ovary  cells
or  human  lymphocytes  (White  et  al., 1979;   Uehleke  et   al.,  1977).    In  a
recent experiment  1n which chloroform was  used at  a higher concentration,  1t
was  found  to Induce  sister  chromatld exchange  1n   cultivated  human lympho-
cytes  (Morimoto and Koizumi,  1983).   In  the  presence of metabolic activation

                                      -10-

-------
(S-9),  chloroform  was  reported  to  be weakly  positive  or  "suggestive"  1n
mutagenlclty  assays  In  Saccharomyces  cerevlsjae  D7  and  DrosophlHa.  In  a
host-mediated assay  with S.  typhlmuMum,  1n the  murlne  bone marrow  micro-
nucleus  test  and   1n   the   Induction  of  murlne  sperm  head  abnormalities
(Agustln  and  L1m-Syl1anco,   1978;  Callen  et  al.,  1980;  Land  et al.,  1981;
Topham, 1980; Gocke et al.,  1981).
4.4.   WEIGHT OF EVIDENCE
    Oral  exposure  to chloroform has  caused hepatic  carcinomas  1n male  and
female  B6C3F1  mice   (NCI,  1976),   renal   carcinomas  and  adenomas  1n  male
Osborne-Mendel  rats  (NCI,  1976) and   1n male  ICI  mice  (Roe  et al.,  1979),
thyroid  tumors  1n  female Osborne-Mendel  rats  (NCI,  1976)  and  an  Increased
Incidence  of  malignant  mammary   gland  tumors  after  chronic  exposure  In
Sprague-Oawley  rats  (Palmer  et   al., 1979).   Evidence  1s  sufficient  to
classify  chloroform  as  an animal  carcinogen.   Although  some  association
between  oral  exposure  to chloroform (presumably as a result  of  chlorinating
drinking  water) and  human  bladder,  Intestinal  and  rectal  cancer has  been
reported  (see  Section  4.1.1.),  the  evidence  for  human cardnogenldty  Is
best  designated  as  limited.  Applying   the   criteria  for  evaluating  the
overall  weight of  evidence  of  cardnogenldty to  humans  proposed  by  the
Carcinogen  Assessment  Group  of   the U.S.   EPA   (Federal  Register,  1984),
chloroform  1s  most  appropriately  classified as a  Group  82,  a probable human
carcinogen.
                                     -11-

-------
                    5.  REGULATORY STANDARDS AND CRITERIA







    The ACGIH  (1983)  recommends  a TWA-TLV  of  10 ppm  (50  mg/m3} and a  STEL



of 50  ppm  (225 mg/m3) for  chloroform  exposure,  and also notes  that  chloro-



form has  Induced  cancer  In animals  by the oral route at  high  and  Interme-



diate dose levels  and  1s  a  suspected  carcinogen for  humans.
                                     -12-

-------
                             6.  RISK ASSESSMENT



6.1.   ACCEPTABLE INTAKE SUBCHRONIC (AIS)



    Chloroform 1s  known to be  carcinogenic to animals  and Is  suspected  of



being  carcinogenic  to  humans.   Data  are  sufficient  for  derivation  of  a



q,*; therefore, It 1s  Inappropriate to  derive an AIS for  this  chemical.



6.2.   ACCEPTABLE INTAKE CHRONIC (AIC)



    Chloroform 1s  known to be  carcinogenic to animals  and 1s  suspected  of



being  carcinogenic  to  humans.   Data  are  sufficient  for  derivation  of  a



q *; therefore, 1t 1s  Inappropriate to  derive an AIC for  this  chemical.



6.3.   CARCINOGENIC POTENCY (q.,*)



6.3.1.   Oral.  The Carcinogen  Assessment  Group  (U.S.  EPA,  1984) used  the



following data:   liver  tumors  In  female  mice  (NCI,  1976); liver  tumors  1n



male mice  (NCI,  1976); kidney  tumors  1n male  rats (NCI,  1976);  and  kidney



tumors 1n male mice (Roe et al.,  1979).   There was no compelling reason  to



select any one of  these data  sets  over the others; therefore,  the geometric



mean  of  the  slopes   (q,*).   7xlO~2  (mg/kg/day)"1,  was  selected.    The



Health  Assessment  Document  on  Chloroform  (U.S.   EPA,   1984)  contains   a



complete discussion of the calculation  of  the q *.



6.3.2.   Inhalation.   Pertinent data  regarding  the  derivation  of   a  q,*



for chloroform Inhalation  were not  located 1n the  available  literature.
                                     -13-

-------
                                7.   REFERENCES

AC6IH  (American  Conference  of  Governmental  Industrial  Hyglenists).   1983.
Threshold Limit  Values  for  Chemical  Substances and  Physical  Agents  1n  the
Workroom  Environment  with Intended  Changes  for  1983-1984.   ACGIH,  Cincin-
nati, OH.  p. 15, 45-46.

Agustln,  J.S.   and   C.Y.   L1m-Syl1anco.   1978.   Mutagenlc  and  clastogenlc
effects of  chloroform.   Bull.  Philadelphia  Blochem. Soc.  1: 17-23.   (Cited
1n U.S. EPA, 1982)

Alavanja, M.,  I. Goldstein  and  M.  Susser.    1978.   A  case control  study  of
gastrointestinal  and  urinary   tract  cancer  mortality  and  drinking  water
chloMnatlon.   In:   Water  Chlor1nat1on:   Environmental   Impact  and  Health
Effects,  Vol.  2, R.L.  Jolley,  H.  Gorchey  and  O.H.  Hamilton,  Jr.,  Ed.   Ann
Arbor  Science  Publishers,  Ann  Arbor, MI.   p.  394-409.   (Cited  In  U.S.  EPA,.
1983b)

Barrows,  M.E.,  S.R.  Petrocelll,  K.J. Macek  and J.  Carroll.  1978.   Blocon-
centratlon and elimination of selected water  pollutants  by blueglll sunflsh.
Am. Chem. Soc., D1v.  Environ. Chem.   18:  345-346.

Bomskl,  H.,  A.  Sobolweska  and  A.  Strakowskl.   1967.   Toxic  damage  of  the
liver  by chloroform  1n  chemical   Industry  workers.   Arch. Gewerbepathol.
Gewerbehy.  24: 127-134.  (Ger.)  (Cited  1n U.S.  EPA, 1982)

-------
Branchflower, R.V. and  L.R.  Pohl.   1981.   Investigation of the  mechanism  of
the potentiation  of  chloroform-induced hepatotoxlcity and  nephrotoxicity  by
methyl n-butyl ketone.  Toxicol.  Appl.  Pharmacol.   16(3):  407-413.

Brenniman,  G.R.,  0.   Vasllomanolakis-Lagos,  J.  Amsel,  T.  Namekata and  A.H.
Wolff.   1978.   Case-control  study  of  cancer  deaths  in Illinois communities
served  by  chlorinated  or  nonchlorinated  water.    In:  Water  Chlorination:
Environmental  Impact and  Health Effects,  R.J. Jolley,  H.  Gorchen  and  H.
Hamilton,   Jr.,   Ed.   Ann   Arbor   Science   Publishers,   Ann  Arbor,   MI.
p. 1043-1057.  (Cited 1n U.S. EPA, 1983b)

Brown,  D.M.,  P.F. Langley, D. Smith  and  O.C.  Taylor.  1974.   Metabolism of
chloroform.   I.  The  metabolism of   14C-chloroform  by  different  species.
Xenobiotica.  4:  151-163.   (Cited in U.S.  EPA, 1982)

Callahan,  M.A.,  M.W.  Shlmak,   N.W.   Gabel,  et   al.   1979.   Water-Related
Environmental Fate of  129  Priority  Pollutants.  Vol. II.  U.S. EPA, Office of
Water  Planning and Standards, Office  of Water and  Waste Management, Washing-
ton,  DC.   EPA 440/4-79-029b.

Callen,  D.F.,  C.R.  Wolf and R.M. Philpot.  1980.   Cytochrome P-450 mediated
genetic  activity  and  cytotoxlclty of  seven  halogenated aliphatic  hydro-
carbons  in  Saccharomyces  cerevisiae.  Mutat.  Res.   77:  55-63.   (CHed  1n
U.S.  EPA,  1982)

Cantor,  K.P.,  R.  Hoover,  T.J. Mason and  L.O. McCabe.  1978.   Association of
cancer  mortality  with halomethanes  1n  drinking  water.  J. Natl. Cancer  Inst.
61(4):  979-985.   (CHed in U.S.  EPA, 1983b)

                                     -15-

-------
Challen,  P.J.R.,  O.E.  H1ck1sh  and  J.  Bedford.   1958.   Chronic  chloroform
Intoxication.   Br.  J.  Ind.  Med.   15:  243-249.   (Cited  In  U.S.  EPA,  1982)

OeSalva,  S.,  A.  Volpe, G.  Leigh  and  T.  Regan.   1975.   Long-term  safety
studies of  a  chloroform-containing  dentifrice and  mouth-rinse In  man.   Food
Cosmet. Toxlcol.  13:  529.   (Cited In U.S.  EPA,  1982}

Eschenbrenner, A.B. and E.  Miller.   1945.   Induction  of  hepatomas  In  mice by
repeated  oral administration of chloroform, with observations  on  sex  differ-
ences.  J. Natl. Cancer Inst.  5:  251-255.   (Cited  In  U.S.  EPA, 1982)

Federal   Register.    1984.   Environmental   Protection   Agency.    Proposed
guidelines for carcinogenic risk assessment.  49 FR 46294-46299.

Fry,  J.,   T.  Taylor  and   D.F.  Hathaway.   1972.    Pulmonary  elimination  of
chloroform and  Its metabolite In  man.   Arch.  Int.  Pharmacodyn.  196:  98-111.
(Cited  In U.S. EPA, 1982)

Gocke,  E., M.T.  King,  K.  Eckhardt and  D.  Wild.   1981.   Mutagenlclty  of
cosmetics  Ingredients  licensed  by  the European  communities.  Mutat.  Res.
90: 91-109.   (Cited In U.S. EPA, 1982)

Gottlieb,  M.S., J.K.  Carr  and  D.T. MorMss.   1981.   Cancer and  drinking
water  In  Louisiana:  Colon  and  rectum.    Int.  Ep1dem1ol.    10(2):  117-125.
(Cited  1n U.S. EPA, 1983b)
                                     -16-

-------
Harris, R.N.,  J.  Ratnayake, J.  Harris,  V.F.  Garry  and M.W. Anders.   1982.
Interactive hepatotoxlclty of chloroform and  carbon  tetrachlorlde.   Toxlcol.
Appl. Pharmacol.  63(2):  281-291.

Heywood, R., R.O. Sortwell, P.R.8. Noel, et  al. .  1979.   Safety  evaluation of
toothpaste containing  chloroform.   III.  Long-term study 1n  beagle  dogs.   J.
Environ. Toxlcol.  2: 835-851.   (Cited In U.S. EPA, 1982)

Hogan,  M.D.,  P.  CM,  D.G.  Hoel  and  T.J.  Mitchell.   1979.    Association
between chloroform  levels  1n  finished drinking  water  supplies  and  various
site-specific  cancer  mortality   rates.   J.  Environ.   Pathol.  Toxlcol.   2:
873-887.  (Cited 1n U.S.  EPA, 1983b)

IARC  (International  Agency  for Research  on  Cancer).   1979.   Chloroform.  In.:
Some  Halogenated Hydrocarbons.   IARC Monographs  on the  Evaluation  of  the
Carcinogenic   Risk   of  Chemicals   to  Humans.    WHO,   IARC,  Lyon,  France.
Vol.  20, p. 401-427.

I1j1ma, M.,  M.G.  Cote and G.L. Plaa.   1983.   A  semlquantltatlve morphologic
assessment  of   chlordecone-potentlated  chloroform hepatotoxlclty.   Toxlcol.
Lett.   17(3-4): 307-314.

Klrkland,  D.J.,  K.L.  Smith and N.O.  Van Abbe.   1981.   Failure  of chloroform
to  Induce  chromosome damage or slster-chromatld  exchanges  In cultured human
lymphocytes  and  failure   to  Induce  reversion  1n  EscheMchla  coll.   Food
Cosmet. Toxlcol.  19(5):  651-656.
                                     -17-

-------
Kutob, S.D. and G.L.  Plaa.   1961.   The effect of acute  ethanol  Intoxication



on chloroform-Induced liver damage.  J. Pharmacol. Exp.  Ther.   135:  245-251.



(Cited 1n U.S.  EPA,  1982)







Land, P.C., E.L.  Owen and H.W.  Llnde.   1981.  Morphologic changes  in  mouse



spermatozoa after exposure  to inhalatlonal anesthetics  during  early  sperma-



togenesls.  Anestheslology.   54 53-56.   (Cited 1n U.S.  EPA,  1982)







McLean,  A.E.M.    1970.   The  effects  of  protein deficiency  and  mlcrosomal



enzyme Induction  by  DOT  and  phenobarbltone on the acute toxldty  of  chloro-



form  and  pyrroHzldlne  alkaloid retrorsine.  Br. J.  Exp. Pathol.   51:  317.



(Cited 1n U.S.  EPA,  1980b)







Morlmoto, K. and  A.  Koizumi.   1983.  Trlhalomethanes  Induce  sister chromatid



exchanges 1n human lymphocytes in  vitro and mouse bone marrow cells 1_n vivo.



Environ. Res.   32(1): 72-79.







Murray,  F.J., B.A.  Schwetz,  J.G. McBrlde and R.E. Staples.   1979.  Toxldty



of  Inhaled  chloroform 1n  pregnant  mice and their offspring.   Toxlcol.  Appl.



Pharmacol.  50: 515-522.  (Cited 1n U.S. EPA,  1982)







NCI  (National  Cancer Institute).   1976.   Report on  Cardnogenesls Bloassay



of Chloroform.  NTIS PB-264-018.   (Cited in U.S.  EPA, 1982)







NIOSH  (National  Institute  for   Occupational  Safety  and  Health).   1974.



Criteria  for  a Recommended  Standard...Occupational  Exposure  to Chloroform.



U.S.  DHEW,  PHS, CDC, Rockvllle, MD.  NTIS PB-246-695.
                                     -18-

-------
Palmer, A.K., A.E. Street, F.J.C. Roe, A.N. Worden  and  N.J.  Van  Abbe.   1979.



Safety  evaluation  of   toothpaste   containing   chloroform.    II.   Long-term



studies 1n rats.   J.  Environ.  Pathol. Toxlcol.   2:  821-833.







Roe,  F.J.C.,  A.K. Palmer,  A.N.  Worden  and  N.J.   Van  Abbe.   1979.   Safety



evaluation  of  toothpaste  containing chloroform.   I.   Long-term studies  1n



mice.  J.  Environ. Toxlcol.   2:  799-819.







Schwetz, B.A., B.K.J. Leong and  P.J.  GehMng.   1974.   Embryo-  and  fetotoxic-



Hy of  Inhaled chloroform  1n  rats.   Toxlcol.  Appl. Pharmacol.   28:  442-451.



(Cited 1n  U.S.  EPA, 1982)







Struba, R.J.   1979.   Cancer  and drinking  water  quality.   Ph.D.  Thesis,



University  of  Worth  Carolina,  Chapel   H111,   NC.   156 p.   Available  from



University  Microfilms   International,  Ann  Arbor,  MI.   Publ.  No.  8022514.



(Cited 1n  U.S.  EPA, 1983b)







Sturrock,  J.  1977.  Lack  of  mutagenlc  effect of halothane  or chloroform on



cultured  cells  using  the azaguanlne test  system.   Br.  J.  Anaesth.   49:



207-210.  (Cited  1n U.S. EPA,  1982)







Taylor, D.C., O.M.  Brown,  R.  Kuble  and  P.P.  Langley.   1974.  Metabolism of



chloroform.   II.  A sex  difference   1n  the metabolism  of  14C-chloroform  1n



mice.  Xenob1ot1ca.  4:  165-174.   (Cited  in U.S.  EPA, 1982)
                                     -19-

-------
Thompson, D.J., S.D. Warner and V.B. Robinson.  1974.   Teratology  studies  1n



orally  administered  chloroform   1n  the  rat  and  rabbit.   Toxlcol.  Appl.



Pharmacol.   29: 348-357.   (Cited  1n U.S.  EPA,  1982)







Topham,  J.C.   1980.  Do  Induced   sperm-head  abnormalities  In mice  specifi-



cally Identify mammalian mutagens  rather  than  carcinogens?  Mutat.  Res.   74:



379-387.  (Cited 1n U.S.  EPA,  1982)







Torkelson,  T.R.,  F.  Oyen and V.K.  Rowe.   1976.   The  toxldty of  chloroform



as  determined  by single and  repeated  exposure of  laboratory animals.   Am.



Ind. Hyg. Assoc. 3.  37:  697-705.   (Cited 1n U.S.  EPA,  1982)







Uehleke, H., T. Werner,  H.  Grelm  and M.  Kramer.   1977.  Metabolic  activation



of  halothanes  and  tests   in  vitro  for  mutagenlclty.   Xenob1ot1ca.   7:



393-400.  (Cited 1n U.S.  EPA,  1982)







U.S.  EPA.   1980a.   Guidelines  and Methodology  Used  in  the Preparation  of



Health  Effects  Assessment  Chapters of  the Consent Decree  Water  Quality Cri-



teria.  Federal Register.  45: 79347-79357.







U.S.  EPA.   1980b.   Ambient Water  Quality Criteria for Chloroform.   Environ-



mental  Criteria and  Assessment  Office,  Cincinnati,  OH.   EPA  440/5-80-033.



NTIS PB 81-117442.  (Cited 1n U.S. EPA, 1982)







U.S.  EPA.   1982.   Hazard Profile  for  Chloroform.  Prepared  by  the Environ-



mental  Criteria  and Assessment Office,  Cincinnati,  OH, OHEA for  the Office



of  Solid Waste and Emergency Response,  Washington, DC.
                                     -20-

-------
U.S. EPA.  1983a.  Methodology and  Guidelines  for  Reportable Quantity Deter-
minations  Based  on  Chronic  Toxicity  Data.   Prepared  by  the  Environmental
Criteria and Assessment Office, Cincinnati, OH,  OHEA  for  the Office of Solid
Waste and Emergency Response, Washington, DC.

U.S. EPA.  1983b.  Review of lexicological  Data  in Support of Evaluation for
Carcinogenic Potential of Chloroform.   Prepared  by the  Carcinogen Assessment
Group,  OHEA,  Washington,  DC for  the  Office  of  Solid  Waste and  Emergency
Response, Washington, DC.

U.S. EPA.   1984.   Health Assessment Document  for  Chloroform.  Environmental
Criteria and Assessment Office, Research  Triangle  Park,  NC.  External Review
Draft.  EPA 600/8-84-004A.  NTIS PB 84-195163.

von  Oettlngen,  W.F.   1964.  The  Halogenated  Hydrocarbons  of  Industrial  and
Toxicological Importance.   Elsevier Co.,  Amsterdam,   p. 77-108.   (Cited  in
U.S. EPA, 1982)

White,  A.E.,  S.  Takehlsa,  E.I.  Eger,  S. Wolff  and  W.C.  Stevens.   1979.
Sister  chromatld exchanges  induced by  inhaled  anesthetics.  Anestheslology.
50: 426-430.  (Cited in U.S.  EPA,  1982)

Wilson,  3.T., C.G.  Enfield, W.J.  Dunlap,  R.L.  Cosby,  D.A.  Foster  and  L.B.
Baskin.  1981.-  Transport and fate  of  selected  organic  pollutants in a sandy
soil.  J. Environ.  Qua!.   10: 501-506.
                                     -21-

-------
Wilson, J.T., 3.F. McNabb, 8.H. Wilson and M.J.  Noonan.   1983.   Blotransfor-



matlon of  selected  organic  pollutants In groundwater.  Dev.  Ind.  Mlcroblol.



24: 225-233.







Young, T.B.,  M.S. Kanarek and  A.A.   Tslatis.   1981.   Epidemiology study  of



drinking water chloMnatlon and Wisconsin female  cancer mortality.   J.  Natl.



Cancer Inst.  67(6): 1191-1198.   (Cited In U.S.  EPA, 1983b)







Zoeteman,  B.C.J., K.  Harmsen,  J.B.H.J.  Unders, C.F.H. Morra and  W.  Slooff.



1980.  Persistent organic pollutants  1n  river water  and  ground  water  of the



Netherlands.  Chemosphere.  9:  231-249.
                                     -22-

-------